Novartis-Amgen’s Aimovig Poised for India Debut
Executive Summary
Novartis is planning to launch Aimovig in India after the migraine therapy was endorsed by an expert panel, but all eyes will be on pricing and how the company’s recent dispute with partner Amgen plays out.
You may also be interested in...
Novartis India's New Chief Has A Full Plate
Ex-AstraZeneca executive Sanjay Murdeshwar will lead Novartis in India. The incoming head faces multiple challenges including balancing profitable growth and access in a largely self-pay market.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet